JAZZ vs. IONS, MRTX, RARE, ARWR, RPRX, PRGO, CORT, SUPN, PCRX, and OMER
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Royalty Pharma (RPRX), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
Jazz Pharmaceuticals received 417 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 80.51% of users gave Jazz Pharmaceuticals an outperform vote while only 60.33% of users gave Ionis Pharmaceuticals an outperform vote.
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Jazz Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Ionis Pharmaceuticals' net margin of -49.49%. Jazz Pharmaceuticals' return on equity of 27.86% beat Ionis Pharmaceuticals' return on equity.
Jazz Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Jazz Pharmaceuticals currently has a consensus target price of $185.86, suggesting a potential upside of 66.58%. Ionis Pharmaceuticals has a consensus target price of $60.18, suggesting a potential upside of 16.96%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than Ionis Pharmaceuticals.
In the previous week, Ionis Pharmaceuticals had 24 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 33 mentions for Ionis Pharmaceuticals and 9 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.87 beat Ionis Pharmaceuticals' score of 0.69 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
Summary
Jazz Pharmaceuticals beats Ionis Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get Jazz Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jazz Pharmaceuticals Competitors List
Related Companies and Tools
Free JAZZ Stock Alerts